Showing results 1 to 1 of 1
Issue Date | Title | Journal Title |
---|---|---|
2022 | Amivantamab in combination with lazertinib in patients with atypical epidermal growth factor receptor (EGFR) mutations excluding exon 20 insertion mutations: Initial results from CHRYSALIS-2 | ANNALS OF ONCOLOGY |